Equities

GlucoTrack Inc

GCTK:NAQ

GlucoTrack Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)0.5602
  • Today's Change-0.003 / -0.50%
  • Shares traded70.45k
  • 1 Year change+28.49%
  • Beta0.1691
Data delayed at least 15 minutes, as of May 10 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

GlucoTrack, Inc. is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is developing an implantable continuous glucose monitoring (CGM) for use by Type 1 diabetes patients as well as insulin-dependent Type 2 patients. It is developing an implantable continuous blood glucose monitor (CBGM). This product is designed to have an approximately two-year implant longevity without the requirement for any wearable components. The CBGM utilizes an intravascular approach, in which the device is implanted subcutaneously and connected to a lead that is placed directly into a blood vessel. This facilitates continuous blood glucose measurements with zero lag time. The Company is also developing the Glucotrack CBGM a companion mobile application and a cloud-based solution to provide real time, data-driven personalized tools to effectively help a user manage their diabetes and assist healthcare providers with making treatment decisions.

  • Revenue in USD (TTM)0.00
  • Net income in USD-7.10m
  • Incorporated2010
  • Employees6.00
  • Location
    GlucoTrack Inc301 Rte 17 North, Ste. 800RUTHERFORD 07070United StatesUSA
  • Phone+1 (201) 842-7715
  • Fax+1 (302) 655-5049
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Pieris Pharmaceuticals Inc42.81m-24.54m13.79m46.00--0.5153--0.3221-22.94-22.9438.0321.640.6382--13.42930,652.20-36.58-28.41-57.30-39.69-----57.33-94.61----0.00--65.288.0326.25---36.82--
Coeptis Therapeutics Holdings Inc0.00-21.27m13.83m5.00--3.14-----0.8922-0.89220.000.12210.00----0.00-266.05-36.90-392.90-37.81------------0.2068------43.40------
Vicapsys Life Sciences Inc0.00-1.08m14.24m2.00---------0.0327-0.03270.00-0.04160.00----0.00-364.66-----------------10.40---------317.25------
Tonix Pharmaceuticals Holding Corp7.77m-116.66m14.51m103.00--0.0954--1.87-8.62-8.620.45721.800.0409----75,417.48-61.38-59.46-68.01-65.9238.97---1,501.78-5,126.731.81--0.0779------0.1874--320.57--
Edesa Biotech Inc0.00-7.72m14.83m16.00--2.50-----2.60-2.600.001.850.00----0.00-79.13---95.05--------------0.00------52.28------
Mannatech Inc131.96m-2.24m14.98m213.00--1.41--0.1136-1.21-1.2170.535.642.921.99854.08619,507.10-4.964.39-12.909.1677.9577.87-1.701.720.5093-5.810.122688.33-3.83-5.3350.13---20.38--
GlucoTrack Inc0.00-7.10m14.99m6.00--3.66-----0.3394-0.33940.000.1530.00----0.00-193.30-94.01-294.60-142.35-------10,447.96----0.0578-------60.02------
Oncotelic Therapeutics Inc70.00k-7.90m15.25m22.00--1.26--217.84-0.02-0.020.00020.03040.0021--3.613,181.82-24.82-25.03-49.08-48.76-----11,722.94-1,692.93---0.47880.5199-------255.12------
Allied Corp21.51k-9.00m15.59m--------724.63-0.0915-0.09150.0002-0.07110.00511.650.1441---214.39-------6,919.57---41,861.41--0.0333-31.86-----56.46--31.30------
Curative Biotechnology Inc0.00-6.02m15.72m4.00---------0.0105-0.01050.00-0.00180.00----0.00-339.98-----------------5.51---------302.92------
Ibio Inc50.00k-20.77m15.93m26.00--0.6525--318.62-21.91-27.300.04372.840.0012--0.01291,923.08-48.41-28.09-113.84-32.63-----41,546.00-1,467.30---518.330.5942---100.00--0.9764--42.90--
Trinity Biotech plc (ADR)56.83m-36.87m16.09m380.00------0.2831-4.82-3.147.42-15.670.75011.763.83149,557.90-48.66-20.30-61.88-29.5434.2239.92-64.87-29.861.27-1.611.55---9.10-10.1515.41---31.08--
Data as of May 10 2024. Currency figures normalised to GlucoTrack Inc's reporting currency: US Dollar USD

Institutional shareholders

2.54%Per cent of shares held by top holders
HolderShares% Held
Sabby Management LLCas of 31 Dec 2023428.91k1.75%
Alerus Financial, NA (Private Banking)as of 31 Dec 202369.28k0.28%
Citadel Securities LLCas of 31 Dec 202339.18k0.16%
Boston Financial Management LLCas of 31 Dec 202326.37k0.11%
Accurate Wealth Management LLCas of 31 Mar 202422.10k0.09%
Virtu Americas LLCas of 31 Dec 202318.91k0.08%
Two Sigma Securities LLCas of 31 Dec 202313.32k0.05%
UBS Securities LLCas of 31 Dec 20234.80k0.02%
Warberg Asset Management LLCas of 31 Dec 20230.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.